Stada Begins Work On Romanian Hub
Investment Of More Than €50m Will Strengthen Supply Chain In Europe
Executive Summary
Stada has begun work on a facility in Romania into which the German giant is investing more than €50m to bolster the European supply chain.
You may also be interested in...
Stampa Urges Investment In European Manufacturing
Fresh from being named as the new president of Medicines for Europe, Medichem CEO Elisabeth Stampa sets out the association’s priorities around investment in European manufacturing, as well as identifying key obstacles that must be overcome to create a sustainable environment for off-patent medicines, in an exclusive interview with Generics Bulletin.
Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount
Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.
Sandoz Gets EU Nod For Higher-Strength Adalimumab
Sandoz has received a positive opinion from the EMA’s CHMP recommending that its high-concentration 100mg/ml adalimumab biosimilar be granted a pan-European marketing authorization. Three generics were also endorsed at the CHMP’s January meeting, including a rival to Forxiga.